To include your compound in the COVID-19 Resource Center, submit it here.

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Dec.

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE